To understand the goals of Operation Warp Speed we must understand Dr. Moncef Slaoui and his connections to Big Pharma and the Gates Foundation.
In mid-May, Donald Trump announced he was appointing Dr. Moncef Slaoui, a former executive with vaccine manufacturer GlaxoSmithKline, to lead Operation Warp Speed, the public-private partnership launched by the Trump administration to rapidly develop and distribute a COVID-19 vaccine. Dr. Slaoui was a Professor of Immunology at the University of Mons, Belgium. Slaoui earned a Ph.D. in Molecular Biology and Immunology from the University Libre de Bruxelles, Belgium and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston.
Following his education, Slaoui joined the pharmaceutical industry, serving on the board of Directors of GlaxoSmithKline between 2006 through 2015. Slaoui served in several senior research & development (R&D) roles with GlaxoSmithKline during his time with the company, including Chairman of Global Vaccines.
More recently, Slaoui sits on the boards of several pharmaceutical companies and biotechnology organizations. In 2016, Slaoui was appointed to the Board of Directors of Moderna Therapeutics, a biotech company that is leading the way for messenger RNA (mRNA) therapeutics and vaccines. Moderna is also developing one of the COVID-19 vaccines which might be administered to the public.
Read More: Operation Warp Speed Head And Gates Foundation Are Pushing BioElectronics And Vaccine Patches
